Publication date: Available online 23 October 2026 Source: European Urology Focus Author(s): Giorgio Gandaglia, Francesco Pellegrino, Ayman Hijazy, Bertrand De Meulder, Thomas Abbott, Asieh Golozar, Mario de Angelis, Rossella Nicoletti, Pawel Rajwa, Juan Gómez Rivas, Carl Steinbeisser, Kishore Reddy Papineni, Tracie Roggenkamp, Daniel Kotik, Timothy Victor, Susan Evans-Axelsson, Alberto Briganti, James N’Dow
Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926001951?dgcid=rss_sd_all
Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926001951?dgcid=rss_sd_all
“Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer.” European Urology Focus.
@article{article45413,
title = {Real-world Data to Assess the Applicability of Randomized Controlled Trials in Newly Metastatic Prostate Cancer},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926001951?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...